HaysMed pulls products as result of meningitis outbreak
Special to The Hays Daily News
As additional information is provided by the Food and Drug Administration about the medications distributed from the New England Compounding Center, HaysMed has pulled and retained any products received from NECC. HaysMed did not receive any methylprednisolone, the drug recalled due to its connection to the recent fungal meningitis outbreak.
Out of an abundance of caution, the FDA and the Kansas Department of Health and Environment have recommended medical facilities follow up with patients who received any injectable product from NECC on or after May 21. HaysMed is following the FDA's recommendation and is sending letters to approximately 150 patients to provide this information and advising them to contact their health care provider or HaysMed if they have any concerns. To date, there are no known cases of complications with NECC medications administered to HaysMed patients.
HaysMed is in contact with state health authorities and will continue to review and monitor information provided by the FDA.